Here's Why You Must Add Hologic (HOLX) To Your Portfolio Now
Zacks Investment Research | Feb 26, 2018 09:42PM ET
Hologic Inc. (NASDAQ:HOLX) has been on a healthy growth trajectory of late. The company’s progress in the domestic and international markets, a strong pipeline of products as well as huge future prospects of the GYN Surgical and Molecular Diagnostics segments make it an attractive pick at the moment. Therefore this Zacks Rank #2 (Buy) stock boasts solid prospects to drive its shares higher in the near term.
The stock has a market cap of $11.01 billion. The company’s expected growth rate for 2018 is 11.6%.
The company has an average positive earnings surprise of 6.3% for the last four quarters. Also, it has a long-term expected earnings growth rate of 9.8%.
The company’s estimate revision trend for the current year has been positive. In the past couple of months, 12 analysts moved north with no southbound estimates witnessed. Earnings estimates have been raised around 6.1% to $2.25 per share over the same time frame.
Let’s find out whether the recent favorable trend is a sustainable one.
Hologic’s first-quarter fiscal 2018 performance was quite promising, primarily on the strength of Molecular Diagnostics. Headquartered in Bedford, MA, the company’s global growth was driven by an increasing market share and utilization of fully automated Panther system along with a continued solid uptake of Aptima women's health products. Notably, Aptima women’s health assays are dominant in the testing labs for detecting chlamydia, gonorrhea, HPV (Human papillomavirus) and trichomonas.
Hologic, Inc. Price
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.